Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended‐Release Oxycodone on Tampering in a Real‐World Settings
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70085 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Karilynn M Rockhill und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Oxycodone, Delayed-Action Preparations. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Collegium Pharmaceutical Inc.
Abstract (Originalsprache)
Purpose
To assess whether exposure to an extended‐release (ER) oxycodone with abuse deterrent properties (ADF) reduced tampering of oxycodone in a real‐world, postmarket setting to address the thinking behind Category 4 labeling by the FDA.
Methods
Data from an observational cross‐sectional study of the general adult population (2022) was used under a causal framework to estimate the confounding‐adjusted odds of tampering oxycodone after exposure to two types of ADF ER oxycodone. The tampering behaviors of those who used only single entity immediate‐release (SE‐IR) oxycodone was used as a comparison. The tampering outcome was defined as use by snorting, smoking, or injecting any oxycodone (ER or SE‐IR). A directed acyclic graph was used to identify covariates. Average treatment effect among the treated was estimated using inverse propensity score weighting combined with survey weights in a regression.
Results
In 2022, 0.14% and 3.0% among the general population reported using the two ER oxycodone groups, while 2.4% used SE‐IR oxycodone. Propensity score analyses with both comparators (common support > 98%) balanced demographic, health, and drug use covariates. After adjustment for selection and confounding bias, among those who used ER oxycodone group 1 the odds ratio of tampering with any form of oxycodone was elevated but not statistically significant (2.25; 95% CI: 0.94, 5.39). The odds ratio of tampering by users of ER oxycodone group 2 was significantly elevated (1.90; 95% CI: 1.08, 3.19).
Conclusions
Tampering of ER oxycodone products by individuals was rare. We found evidence suggestive of elevated odds of tampering behaviors with use of an ADF ER oxycodone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, Colorado, USA.
ORCID-Profile: Joshua C Black
Förderung
- Collegium Pharmaceutical Inc
Zitieren
APA
Rockhill, K. M., Burkett, H., Dart, R., & Black, J. C. (2025). Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended‐Release Oxycodone on Tampering in a Real‐World Settings. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70085
Vancouver
Rockhill KM, Burkett H, Dart R, Black JC. Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended‐Release Oxycodone on Tampering in a Real‐World Settings. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70085
BibTeX
@article{Rockhill2025,
author = {Rockhill, Karilynn M and Burkett, Hannah and Dart, Richard and Black, Joshua C},
title = {Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended‐Release Oxycodone on Tampering in a Real‐World Settings},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70085}
}
EUVIMED